Phase I Clinical Evaluation of rDEN4Δ30-200,201: A Live Attenuated Dengue 4 Vaccine Candidate Designed for Decreased Hepatotoxicity

The rDEN4Δ30-200,201 is a live attenuated DENV-4 vaccine candidate specifically designed to further attenuate the rDEN4Δ30 parent virus. In the present study, 28 healthy adult volunteers were randomized to receive either 10(5) plaque-forming unit (PFU) of vaccine (20) or placebo (8) as a single subc...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: McArthur, Julie H., Durbin, Anna P., Marron, Jennifer A., Wanionek, Kimberli A., Thumar, Bhavin, Pierro, Dennis J., Schmidt, Alexander C., Blaney, Joseph E., Murphy, Brian R., Whitehead, Stephen S.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2008
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2590927/
https://ncbi.nlm.nih.gov/pubmed/18981503
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares